What is BIOTRICITY INC's earnings per share (EPS)?

BIOTRICITY INC (BTCY) reported diluted earnings per share of -$0.12 for fiscal year 2026. This represents a 79.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

BIOTRICITY INC (BTCY) Financials

BTCY

Trailing 12 months to June 30, 2026

Revenue $16.4M +13.4% YoY

Net Income -$2.7M +50.1% YoY

EPS (Diluted) -$0.13 +37.6% YoY

Operating Cash Flow $162K +112.8% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Jun 30, 2026 Reported Aug 19, 2026 Currency USD FYE March

Newest figures come from the 10-Q for Q1 FY2027, filed Aug 19, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BTCY SEC filings page.

BIOTRICITY INC (BTCY) reported $16.4M in revenue over the twelve months to Jun 30, 2026, up 13.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BTCY FY2026 2026-10-04

Biotricity's improving sales economics now produce operating profit, but interest costs and a severely stretched balance sheet still absorb earnings.

Gross margin expansion from 69.3% in FY2024 to 80.9% in FY2026, alongside declining overhead, shows the operating turnaround came from better unit economics and cost absorption rather than sales growth alone. Yet FY2026 operating profit of $1.7M remained below interest expense, leaving the company with a net loss and showing that financing costs still outweigh the operating surplus.

The balance sheet is structurally strained: a 0.2x current ratio means current assets were only a fraction of near-term liabilities, while equity stood at -$34.7M. Reported liquidity equaled 2.5 months of FY2026 operating outflow, so the financing structure—not just the income statement—matters to interpreting the business.

Cash conversion remains incomplete: operating cash flow improved from -$2.4M in FY2025 to -$719K in FY2026, but stayed negative even after operating income turned positive. FY2026 financing cash flow of $558K indicates that cash movement still included external funding rather than being supplied solely by operations.

Financial Health Signals

Financial health score not available

BIOTRICITY INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

5/8

BIOTRICITY INC passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

BIOTRICITY INC reported a net loss of $2.4M while operations used $719K of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

0.50x

BIOTRICITY INC earns $0.50 in operating income for every $1 of interest expense ($1.7M vs $3.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$4.3M

YoY+10.4%

QoQ+0.6%

5Y CAGR+19.4%

BIOTRICITY INC generated $4.3M in revenue in Q1 2027. This represents an increase of 10.4% from the same quarter a year earlier. Against the prior quarter it is up 0.6%.

EBITDA

$160K

YoY-43.7%

BIOTRICITY INC's EBITDA was $160K in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 43.7% from the same quarter a year earlier.

Net Income

-$959K

YoY-42.8%

QoQ-196.0%

BIOTRICITY INC reported -$959K in net income in Q1 2027. This represents a decrease of 42.8% from the same quarter a year earlier. Against the prior quarter it is down 196.0%.

EPS (Diluted)

-$0.05

YoY-58.6%

QoQ-187.5%

BIOTRICITY INC earned -$0.05 per diluted share (EPS) in Q1 2027. This represents a decrease of 58.6% from the same quarter a year earlier. Against the prior quarter it is down 187.5%.

Cash & Balance Sheet

Cash & Debt

$467K

YoY+19.2%

QoQ+211.4%

5Y CAGR+18.3%

10Y CAGR+30.0%

BIOTRICITY INC held $467K in cash as of Q1 2027; long-term debt is not reported for that period.

Shares Outstanding

20M

YoY-24.4%

QoQ0.0%

5Y CAGR-13.2%

10Y CAGR+2.4%

BIOTRICITY INC had 20M shares outstanding in Q1 2027. This represents a decrease of 24.4% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q1 2027.

Dividends Per Share

Not reported for Q1 2027.

Margins & Returns

Gross Margin

82.5%

YoY+2.1pp

QoQ+2.6pp

5Y change+16.2pp

BIOTRICITY INC's gross margin was 82.5% in Q1 2027, indicating the percentage of revenue retained after direct costs. This is up 2.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.6 percentage points.

Operating Margin

3.7%

YoY-3.6pp

QoQ-12.6pp

BIOTRICITY INC's operating margin was 3.7% in Q1 2027, reflecting core business profitability. This is down 3.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 12.6 percentage points.

Net Margin

-22.4%

YoY-5.1pp

QoQ-14.8pp

BIOTRICITY INC's net profit margin was -22.4% in Q1 2027, showing the share of revenue converted to profit. This is down 5.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 14.8 percentage points.

Return on Equity

Not reported for Q1 2027.

Capital Allocation

R&D Spending

$673K

YoY-3.3%

QoQ-20.0%

5Y CAGR+2.7%

BIOTRICITY INC invested $673K in research and development in Q1 2027. This represents a decrease of 3.3% from the same quarter a year earlier. Against the prior quarter it is down 20.0%.

Share Buybacks

Not reported for Q1 2027.

Capital Expenditures

Not reported for Q1 2027.

BTCY Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BTCY quarterly income statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1610-K	FY1510-K	FY1410-K
Revenue	$16.4M	$16.0M+16.0%	$13.8M+14.3%	$12.1M+25.2%	$9.6M+26.0%	$7.7M+126.0%	$3.4M+138.7%	$1.4M+256.0%	$398K	N/A	N/A	N/A	N/A
Cost of Revenue	$3.0M	$3.0M-5.5%	$3.2M-13.0%	$3.7M-11.7%	$4.2M+36.3%	$3.1M+45.8%	$2.1M+126.6%	$932K+175.5%	$338K	N/A	N/A	N/A	N/A
Gross Profit	$13.4M	$12.9M+22.6%	$10.6M+26.4%	$8.4M+53.6%	$5.4M+19.1%	$4.6M+259.1%	$1.3M+162.0%	$486K+711.4%	$60K	N/A	N/A	N/A	N/A
R&D Expenses	$2.7M	$2.8M+28.2%	$2.2M-16.2%	$2.6M-20.4%	$3.2M+17.7%	$2.7M+33.3%	$2.1M+51.0%	$1.4M+4.1%	$1.3M-25.7%	$1.8M	N/A	$1.1M+37.3%	$833K
SG&A Expenses	$9.1M	$8.5M-21.8%	$10.9M-25.7%	$14.6M-17.1%	$17.6M-5.1%	$18.6M+47.7%	$12.6M	N/A	N/A	N/A	N/A	N/A	$874K
Operating Income	$1.6M	$1.7M+169.1%	-$2.4M+72.3%	-$8.8M+42.7%	-$15.4M+7.9%	-$16.7M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EBITDA	N/A	$1.7M+169.5%	-$2.4M+72.3%	-$8.8M+42.7%	-$15.4M+8.0%	-$16.7M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$3.4M	$3.4M+3.1%	$3.3M+8.1%	$3.0M+64.1%	$1.8M+43.3%	$1.3M+745.6%	$152K	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.7M	-$2.4M+71.5%	-$8.4M+40.3%	-$14.1M+24.5%	-$18.7M+35.9%	-$29.1M-88.0%	-$15.5M	N/A	N/A	N/A	N/A	N/A	-$1.7M
EPS (Basic)	N/A	-$0.12+79.3%	-$0.56+66.6%	-$1.66+26.4%	-$2.26-239.2%	-$0.67-51.8%	-$0.44	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.13	-$0.12+79.3%	-$0.56	-$1.66	-$2.26	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	27M+26.9%	22M	9M	9M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Revenue	$4.3M+10.4%	$4.3M+14.8%	$4.0M+10.2%	$3.9M+18.9%	$3.9M+21.0%	$3.7M+16.5%	$3.6M+21.7%	$3.3M+13.0%
Cost of Revenue	$746K-1.5%	$852K+17.6%	$736K-13.9%	$704K-12.8%	$757K-9.7%	$724K-20.0%	$855K+6.2%	$808K-9.5%
Gross Profit	$3.5M+13.3%	$3.4M+14.1%	$3.3M+17.6%	$3.2M+29.4%	$3.1M+31.9%	$3.0M+31.1%	$2.8M+27.5%	$2.5M+23.0%
R&D Expenses	$673K-3.3%	$842K+47.0%	$624K+13.1%	$603K+16.4%	$696K+35.5%	$573K-19.2%	$551K+21.7%	$518K-25.8%
SG&A Expenses	$2.7M+26.2%	$1.9M-42.9%	$2.2M-8.2%	$2.3M+2.5%	$2.1M-27.9%	$3.3M-29.2%	$2.4M-20.5%	$2.2M-35.5%
Operating Income	$158K-43.9%	$695K+181.2%	$441K+360.9%	$274K+189.0%	$282K+125.2%	-$855K+71.9%	-$169K+86.8%	-$308K+85.9%
EBITDA	$160K-43.7%	N/A	$442K+364.1%	N/A	$283K+125.4%	-$854K+71.9%	-$167K+86.9%	-$306K+86.0%
Interest Expense	$852K+0.2%	$841K-5.7%	$810K-4.6%	$860K+14.4%	$850K+10.6%	$892K+9.4%	$850K+7.5%	$752K-0.2%
Net Income	-$959K-42.8%	-$324K+83.3%	-$717K+41.7%	-$691K+55.8%	-$672K+81.8%	-$1.9M+53.7%	-$1.2M+56.2%	-$1.6M+57.7%
EPS (Basic)	-$0.05-58.6%	-$0.02+71.9%	-$0.04+22.2%	-$0.03+60.3%	-$0.03+94.1%	-$0.06+87.8%	-$0.05+84.1%	-$0.07+83.4%
EPS (Diluted)	-$0.05-58.6%	-$0.02	-$0.04+22.2%	-$0.03+60.3%	-$0.03	-$0.06	-$0.05	-$0.07
Diluted Shares (Avg)	23M-12.1%	N/A	28M+13.9%	27M+19.0%	26M	N/A	24M	22M

Not reported in any period shown, so not listed: Income Tax.

BTCY Balance Sheet

BTCY quarterly balance sheet

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1610-K	FY1510-K	FY1410-K
Total Assets	$6.4M+14.3%	$5.6M-5.1%	$5.9M-8.7%	$6.5M-61.0%	$16.7M+275.8%	$4.4M+121.4%	$2.0M+308.5%	$491K-47.2%	$929K	$68K-87.0%	$519K-0.2%	$520K
Current Assets	$5.9M+26.2%	$4.6M+3.8%	$4.5M-5.3%	$4.7M-69.2%	$15.3M+254.6%	$4.3M+160.5%	$1.7M+262.5%	$458K-48.9%	$896K	$35K-92.9%	$486K-6.5%	$520K
Cash & Equivalents	$150K-59.0%	$365K-53.5%	$786K+37.8%	$570K-95.3%	$12.1M+448.1%	$2.2M+131.8%	$950K+1392.4%	$64K-92.5%	$844K	$21K-95.0%	$411K-8.5%	$449K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$1.3M-13.8%	$1.6M-17.2%	$1.9M-19.6%	$2.3M+177.2%	$843K+209.3%	$272K+217.9%	$86K+248.4%	$25K	N/A	N/A	N/A	N/A
Accounts Receivable	$2.9M+76.8%	$1.7M+12.9%	$1.5M+20.0%	$1.2M-39.0%	$2.0M+31.9%	$1.5M+212.8%	$486K+133.6%	$208K	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$41.1M+9.2%	$37.7M+0.7%	$37.4M+41.9%	$26.4M+40.0%	$18.8M+67.0%	$11.3M+125.2%	$5.0M+120.6%	$2.3M+200.0%	$756K	$4.1M+135.2%	$1.8M+898.8%	$176K
Current Liabilities	$37.1M+80.0%	$20.6M-9.1%	$22.7M+103.4%	$11.2M+129.3%	$4.9M-53.6%	$10.5M+175.8%	$3.8M+67.7%	$2.3M	N/A	N/A	$413K+134.8%	$176K
Non-Current Liabilities	$4.0M-76.6%	$17.0M+15.7%	$14.7M-3.2%	$15.2M+8.9%	$14.0M+1687.1%	$781K-35.0%	$1.2M	$0	N/A	N/A	$1.3M	$0
Total Equity	-$34.7M-8.3%	-$32.0M-1.7%	-$31.5M-58.6%	-$19.8M-825.3%	-$2.1M+68.6%	-$6.8M-127.7%	-$3.0M-68.8%	-$1.8M-1126.1%	$173K	-$4.1M-228.3%	-$1.2M-460.3%	$344K
Retained Earnings	-$142.6M-2.2%	-$139.4M-9.4%	-$127.5M-13.3%	-$112.6M-21.0%	-$93.0M-48.1%	-$62.8M-35.5%	-$46.4M-32.3%	-$35.0M-32.5%	-$26.4M	-$16.5M-78.9%	-$9.2M-128.3%	-$4.0M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Total Assets	$6.0M-0.2%	$6.4M+14.3%	$5.7M-5.0%	$6.3M+19.5%	$6.0M+11.4%	$5.6M-5.1%	$6.0M+9.1%	$5.3M-22.4%
Current Assets	$5.6M+8.8%	$5.9M+26.2%	$5.0M+2.5%	$5.5M+36.2%	$5.1M+25.7%	$4.6M+3.8%	$4.9M+23.6%	$4.1M-21.5%
Cash & Equivalents	$467K+19.2%	$150K-59.0%	$256K-49.7%	$308K+78.0%	$391K+288.5%	$365K-53.5%	$510K+498.9%	$173K-85.6%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$1.4M-20.1%	$1.3M-13.8%	$2.0M+25.8%	$2.3M+24.1%	$1.8M-6.8%	$1.6M-17.2%	$1.6M-23.4%	$1.8M-14.6%
Accounts Receivable	$2.4M+28.9%	$2.9M+76.8%	$1.6M+27.7%	$2.1M+39.9%	$1.9M+22.6%	$1.7M+12.9%	$1.2M-21.5%	$1.5M-6.8%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$41.4M+6.7%	$41.1M+9.2%	$39.9M+5.3%	$39.7M+9.0%	$38.8M+10.3%	$37.7M+0.7%	$37.9M+17.7%	$36.5M+12.9%
Current Liabilities	$37.3M+71.2%	$37.1M+80.0%	$23.8M+12.6%	$23.6M+9.9%	$21.8M+6.0%	$20.6M-9.1%	$21.1M+13.5%	$21.5M+20.6%
Non-Current Liabilities	$4.1M-76.0%	$4.0M-76.6%	$16.1M-3.9%	$16.1M+7.7%	$17.0M+16.5%	$17.0M+15.7%	$16.8M+23.5%	$15.0M+3.4%
Total Equity	-$35.4M-8.0%	-$34.7M-8.3%	-$34.2M-7.2%	-$33.4M-7.2%	-$32.8M-10.1%	-$32.0M-1.7%	-$31.9M-15.1%	-$31.2M-16.6%
Retained Earnings	-$143.6M-2.5%	-$142.6M-2.2%	-$142.1M-3.4%	-$141.0M-1.1%	-$140.2M-0.5%	-$139.4M-9.4%	-$137.4M-11.6%	-$139.4M-16.1%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

BTCY Cash Flow Statement

BTCY quarterly cash flow statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1610-K	FY1510-K	FY1410-K
Operating Cash Flow	$162K	-$719K+69.8%	-$2.4M+64.4%	-$6.7M+50.6%	-$13.5M+10.7%	-$15.2M-36.8%	-$11.1M-40.9%	-$7.9M	N/A	N/A	N/A	-$2.0M-42.1%	-$1.4M
Depreciation & Amortization	N/A	$6K0.0%	$6K0.0%	$6K0.0%	$6K+157.9%	$2K-99.9%	$2.5M+2584.8%	$92K	N/A	N/A	N/A	$0	$0
Stock-Based Compensation	N/A	$26K-98.2%	$1.5M+42.5%	$1.0M+58.4%	$648K-29.1%	$914K+15.6%	$791K-67.2%	$2.4M+66.0%	$1.5M+44.8%	$1.0M	$405K-82.1%	$2.3M	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$30K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$15.2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	-$30K	N/A	N/A	N/A	N/A	N/A	$0	$0
Financing Cash Flow	-$69K	$558K-71.1%	$1.9M-71.4%	$6.7M+236.8%	$2.0M-92.0%	$25.2M+106.2%	$12.2M+37.4%	$8.9M	N/A	N/A	N/A	$2.0M+16.4%	$1.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	$603K+235.0%	$180K	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Operating Cash Flow	$507K+235.8%	-$21K+94.8%	-$740K-740.4%	$416K+204.7%	-$373K+75.0%	-$401K+65.6%	-$88K+93.3%	-$397K+83.4%
Depreciation & Amortization	$1K0.0%	$1K0.0%	$1K-0.1%	N/A	$1K0.0%	$1K0.0%	$1K0.0%	$1K0.0%
Stock-Based Compensation	$340K+5628.2%	N/A	N/A	N/A	$6K-89.9%	N/A	N/A	N/A
Financing Cash Flow	-$191K-143.8%	-$92K-155.5%	$721K+69.7%	-$508K-207.8%	$436K-49.8%	$165K-90.8%	$425K+118.4%	$471K-86.3%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

BTCY Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BTCY quarterly financial ratios

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1610-K	FY1510-K	FY1410-K
Gross Margin	80.9%+4.3pp	76.6%+7.3pp	69.3%+12.8pp	56.5%-3.3pp	59.7%+22.1pp	37.6%+3.3pp	34.3%+19.2pp	15.0%	N/A	N/A	N/A	N/A
Operating Margin	10.6%+28.3pp	-17.8%+55.4pp	-73.2%	-159.9%	-218.8%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-15.0%+46.0pp	-61.1%	-116.8%	-193.6%	-380.8%	-457.7%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-496.1%
Return on Assets	-37.3%+112.0pp	-149.3%+87.9pp	-237.2%+49.4pp	-286.6%-111.9pp	-174.7%+174.4pp	-349.1%	N/A	N/A	N/A	N/A	N/A	-328.2%
Current Ratio	0.16-0.1x	0.220.0x	0.20-0.2x	0.42-2.7x	3.15+2.7x	0.410.0x	0.44+0.2x	0.20	N/A	N/A	1.18-1.8x	2.95
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	4.36	N/A	N/A	0.51
Asset Turnover	2.480.0x	2.44+0.4x	2.03+0.5x	1.48+1.0x	0.46-0.3x	0.76+0.1x	0.71-0.1x	0.81	N/A	N/A	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	-198.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Gross Margin	82.5%+2.1pp	80.0%-0.5pp	81.5%+5.2pp	81.9%+6.6pp	80.5%+6.6pp	80.4%+8.9pp	76.4%+3.5pp	75.3%+6.1pp
Operating Margin	3.7%-3.6pp	16.3%+39.4pp	11.1%+15.7pp	7.0%+16.5pp	7.3%+42.2pp	-23.1%+72.7pp	-4.7%+38.4pp	-9.4%+66.2pp
Net Margin	-22.4%-5.1pp	-7.6%+44.6pp	-18.0%+16.0pp	-17.8%+30.0pp	-17.3%	-52.3%	-34.0%+60.5pp	-47.8%
Return on Assets	-15.9%-4.8pp	-5.0%+29.3pp	-12.6%+7.9pp	-10.9%+18.6pp	-11.1%+57.0pp	-34.3%+36.1pp	-20.5%+30.6pp	-29.5%+24.6pp
Current Ratio	0.15-0.1x	0.16-0.1x	0.210.0x	0.230.0x	0.240.0x	0.220.0x	0.230.0x	0.19-0.1x
Asset Turnover	0.71+0.1x	0.660.0x	0.70+0.1x	0.610.0x	0.64+0.1x	0.66+0.1x	0.60+0.1x	0.62+0.2x

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, FCF Margin.

Note: Shareholder equity is negative (-$34.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.16), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
BIOTRICITY INC BTCY	FY2026	$16.0M	-$2.4M	-15.0%	N/A	—
GUIDED THERAPEUTCS INC GTHP	FY2025	$767K	-$3.2M	N/A	$19.3M	—
CS DIAGNOSTICS CORP CSDX	FY2024	N/A	$761	N/A	$2.1M	—
PETVIVO HOLDINGS INC PETV	FY2026	$1.1M	-$10.5M	N/A	$28.3M	—

Where BIOTRICITY INC Ranks

Frequently Asked Questions

What is BIOTRICITY INC's annual revenue?

BIOTRICITY INC (BTCY) reported $16.0M in total revenue for fiscal year 2026. This represents a 16.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is BIOTRICITY INC's revenue growing?

BIOTRICITY INC (BTCY) revenue grew by 16.0% year-over-year, from $13.8M to $16.0M in fiscal year 2026.

Is BIOTRICITY INC profitable?

No, BIOTRICITY INC (BTCY) reported a net income of -$2.4M in fiscal year 2026, with a net profit margin of -15.0%.

What is BIOTRICITY INC's EBITDA?

BIOTRICITY INC (BTCY) had EBITDA of $1.7M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is BIOTRICITY INC's gross margin?

BIOTRICITY INC (BTCY) had a gross margin of 80.9% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is BIOTRICITY INC's operating margin?

BIOTRICITY INC (BTCY) had an operating margin of 10.6% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is BIOTRICITY INC's net profit margin?

BIOTRICITY INC (BTCY) had a net profit margin of -15.0% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is BIOTRICITY INC's operating cash flow?

BIOTRICITY INC (BTCY) recorded an outflow of $719K in operating cash flow during fiscal year 2026, representing cash used by core business activities.

What are BIOTRICITY INC's total assets?

BIOTRICITY INC (BTCY) had $6.4M in total assets as of fiscal year 2026, including both current and long-term assets.

How much does BIOTRICITY INC spend on research and development?

BIOTRICITY INC (BTCY) invested $2.8M in research and development during fiscal year 2026.

How many shares does BIOTRICITY INC have outstanding?

BIOTRICITY INC (BTCY) had 20M shares outstanding as of fiscal year 2026.

What is BIOTRICITY INC's current ratio?

BIOTRICITY INC (BTCY) had a current ratio of 0.16 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.

What is BIOTRICITY INC's return on assets (ROA)?

BIOTRICITY INC (BTCY) had a return on assets of -37.3% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

How does BIOTRICITY INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2026, BIOTRICITY INC (BTCY) held $150K in cash, cash equivalents and investments, and reported an operating cash outflow of $719K over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is BIOTRICITY INC's debt-to-equity ratio negative or not reported?

BIOTRICITY INC (BTCY) has negative shareholder equity of -$34.7M as of fiscal year 2026, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is BIOTRICITY INC's Piotroski F-Score?

BIOTRICITY INC (BTCY) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are BIOTRICITY INC's earnings high quality?

BIOTRICITY INC (BTCY) reported a net loss of $2.4M while operations used $719K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can BIOTRICITY INC cover its interest payments?

BIOTRICITY INC (BTCY) has an interest coverage ratio of 0.50x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.